Nxera Pharma Co., Ltd. (4565) Press Release
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
Earlier from Nxera Pharma
- Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026
- Nxera Pharma Webinar for Financial Results Presentation - 2Q2026
- OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical Companies and Cloud and AI Infrastructure Technology Providers
- Nxera Pharma: Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea